- Compugen (CGEN +5.4%) moves up today after saying it's established a Scientific Advisory Board to guide its pipeline development.
- The board will focus on advancing activities in the fields ofimmunology and oncology, including its early stage pipeline of therapeutic proteins and monoclonal antibodies.
- The members include four renowned translational scientists and clinicians in oncology and immunology: Charles Drake, MD, PhD, Associate Professor of Oncology, Immunology and Urology at Johns Hopkins Kimmel Cancer Center; Iain McInnes, MD, PhD, Director of the Institute of Infection, Immunity, and Inflammation at the University of Glasgow; Antoni Ribas, MD, PhD, Professor at the Department of Medicine, Hematology/Oncology, UCLA; and Howard Soule, PhD, EVP and Chief Science Officer, Prostate Cancer Foundation.
Compugen establishs Advisory Board to guide pipeline development
Aug 26 2013, 13:19 ET